107 results about "Pharmaceutical Dose Form" patented technology

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Methods and apparatus (10) for Raman spectral analysis of a sample (12), such as a pharmaceutical dosage form, are disclosed. Delivery optics (16) are used to deliver probe light to a delivery region (13) on the sample, and collection optics (20) are used to collect, from a collection region (17) on the sample spaced from the delivery region, the probe light following scattering through the sample. Each of a plurality of target Raman spectral features are measured in the collected light, and a spectral distortion of the collected light arising during scattering through the sample is determined. A property of the sample is then quantified using the target Raman spectral features in combination with the determined spectral distortion, such that the quantified property is compensated for the spectral distortion.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses a yunaconitine derivative and application of the yunaconitine derivative in preparation of hypoglycemic and antioxidant drugs, the yunaconitine derivative has a chemical structure as shown in a formula 1a or 1b, and the invention further provides application of the yunaconitine derivative in preparation of PTP1B inhibitors. The dosage form of the medicine is selected from at least one of a tablet, a capsule, a granule, a dripping pill, a suspension, syrup, an enteric-coated preparation, an emulsion suspension and an injection. The yunaconitine derivative disclosed by the invention is high in bioavailability and clinical use value, provides a candidate lead compound for research and development of novel preparations of hypoglycemic and antioxidant drugs, and has potential application value in the fields of hypoglycemic and antioxidant targeted drugs, probe design and fluorescent biomarkers.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The present invention refers to a liquid pharmaceutical Cetrorelix composition comprising a stabilizing agent selected from poloxamer having an t average molecular weight of 7,000-12,000 g / mol and / or benzyl alcohol, a pharmaceutical dosage form comprising said liquid pharmaceutical composition, and their use in inhibiting premature luteinizing hormone surges in woman undergoing controlled ovarian stimulation. Further, a method for preparing the liquid pharmaceutical Cetrorelix composition and pharmaceutical dosage form is disclosed.

An oral pharmaceutical dosage form, which is intended to provide the desired retention in an individual on the basis of geometric differences between dosage form states before and after administration. The oral pharmaceutical dosage form comprises swellable and expandable material (5). The material (5), upon swelling or expansion, drives the overall size of the oral pharmaceutical dosage form to expand, thereby allowing the oral pharmaceutical dosage form to remain in the stomach for a desired period of time.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.

To provide a method and system of forming a pharmaceutical dosage form within a portion of a blister packaging 1.SOLUTION: The method includes a step of providing a blister packaging for the dosage form with depressions 4. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions 4. A binding liquid is then deposited in a pattern on the powder layer within the depressions 4, to bind the particles of the powder layer and form an incremental wetted layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging 1.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The present disclosure generally relates to the use of polyvinyl alcohol (PVA) in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of PVA in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

Disclosed are quinoline compounds having a structural formula represented by the following formula: and wherein Cy, R1, R4a, R4b and n are as described herein. These compounds may be prepared as compositions, e.g., pharmaceutical compositions, or prepared as dosage forms, e.g., pharmaceutical dosage forms, and may be used in the prevention and treatment of various conditions in mammals, including humans, such as, for example, mammals. Including non-limiting examples of diabetic complications, inflammation, neurodegeneration, obesity, cancer, ischemia / reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases associated with RAGE activity.

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.

The present application relates to a solid dispersion comprising amorphous besudil. Also provided are pharmaceutical dosage forms comprising the solid dispersion comprising amorphous besudil as an active pharmaceutical ingredient, and methods of using the pharmaceutical dosage forms in the treatment of diseases or disorders modulated by ROCK.

The invention relates to a pharmaceutical dosage form for oral administration comprising (i) an intragranular phase, which comprises Sertraline or a physiologically acceptable salt thereof; one or more intragranular fillers (preferably selected from one or more sugar alcohols or sugars; preferably mannitol or lactose, more preferably mannitol); one or more intragranular antioxidants (preferably selected from butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), tocopherol or derivatives thereof, ascorbic acid or derivatives thereof, sodium metabisulphite, propyl gallate, sodium thiosulphate, or any combination thereof, more preferably ascorbic acid); (ii) an extragranular phase, which comprises one or more extragranular fillers (preferably mannitol, microcrystalline cellulose, lactose, or any combination thereof); and (iii) optionally, a film coating. The invention further relates to a process for manufacture by wet granulation, wherein the antioxidant is preferably dissolved in the granulation liquid.

Apparatus and methods for spectral analysis of a sample are described, for example for carrying out Raman or other optical or spectroscopic analysis of samples such as pharmaceutical dosage forms, including oral solid dosage forms such as tablets or capsules. Such apparatus may comprise delivery optics arranged to direct probe light to a delivery region of the sample, collection optics arranged to collect probe light scattered from a collection region of the sample, and a spectrometer having an entrance port, the spectrometer being arranged to receive the collected probe light from the collection optics at the entrance port of the spectrometer, and to detect spectral features in the received probe light. In particular, the collection optics may comprise Koehler integration optics arranged to process the collected probe light such that the collected light from each point of the collection region is distributed across the entrance port of the spectrometer.

Methods and apparatus (10) for Raman spectral analysis of a sample (12), such as a pharmaceutical dosage form, are disclosed. Delivery optics (16) are used to deliver probe light to a delivery region (13) on the sample, and collection optics (20) are used to collect, from a collection region (17) on the sample spaced from the delivery region, the probe light following scattering through the sample. Each of a plurality of target Raman spectral features are measured in the collected light, and a spectral distortion of the collected light arising during scattering through the sample is determined. A property of the sample is then quantified using the target Raman spectral features in combination with the determined spectral distortion, such that the quantified property is compensated for the spectral distortion.

The invention relates to a pharmaceutical dosage form filled with formulations for once-a-day oral administration of deferiprone and deferasirox. Both formulations are in form of coated pellets or coated minitablets. The invention is directed to the claimed pharmaceutical dosage form for use in the treatment of diseases which cause an overload of iron.

The present invention is to provide an amorphous solid dispersion comprising elacestrant dihydrochloride of formula (I), in combination with one or more pharmaceutically acceptable excipients such as a stabilizing agent including a polymer and / or an alkalizing agent. Additionally, the invention provides a process for the preparation of such amorphous solid dispersions and an amorphous form of elacestrant dihydrochloride. The resulting amorphous form or amorphous solid dispersions are advantageous for the formulation of pharmaceutical dosage forms and compositions, enhancing the bioavailability and stability of elacestrant dihydrochloride.

The utility model discloses a multifunctional medicine dividing device, which relates to the technical field of medical assistance and comprises a crushing box, a liquid dividing mechanism is arranged on one side of the crushing box, a medicine cutting mechanism is arranged on one side of the liquid dividing mechanism, a storage mechanism is arranged on one side of the medicine cutting mechanism, and the crushing box comprises a box body. And a feeding opening is formed in the top of the box body, and a medicine guiding plate is fixedly connected to the surface of the feeding opening. According to the utility model, the crushing box, the box body, the medicine guide plate, the feeding hole, the crushing roller, the inclined plate, the sliding plate, the powder storage box and the medicine pouring hole are matched, the motor drives the crushing roller to crush solid medicines, and the powder is subpackaged after being formed, so that accurate metering and taking are facilitated, the risk of adverse reaction possibly caused by inaccurate dosage is reduced, and the working efficiency is improved. The medicine is convenient for patients to take, avoids the taking difficulty caused by overlarge dosage form or difficulty in accurately segmenting the dosage, and is beneficial to improving the safety and effectiveness of medicine treatment.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

The present invention relates to an orally administrable pharmaceutical dosage form configured to target delivery to the distal portion of the gastrointestinal tract of a human subject, the pharmaceutical dosage form comprising lanthanum or a pharmaceutically acceptable salt or oxide thereof. The present invention further relates to a pharmaceutical dosage form used in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or a pharmaceutical dosage form used in the treatment of one or more of nephrolithiasis, nephrocalcinosis or oxalosis in a human subject.